Global Acromegaly and Gigantism Drugs Market Size 2019 Demand, Supply and Forecast 2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 98

Report ID: 21566

Gigantism refers to abnormally high linear growth due to excessive action of insulinlike growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood.
The global acromegaly and gigantism treatment market can be segmented into treatment, end users, and geographical expansion. On the basis of treatment, the market is divided into surgery, radiation therapy, and medication. The medication segment can be further divided into different drug types such as somatostatin analogs, GH receptor antagonists, dopamine agonists and others. The medication segment is expected to hold a significant market share during the forecast period due to factors such as effectiveness of drugs, noninvasive and lesser side effects than radiation therapies, and strong pipeline portfolio. 

The global Acromegaly and Gigantism Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Acromegaly and Gigantism Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acromegaly and Gigantism Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Ipsen
Novartis
Pfizer
...

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Somatostatin Analogs
GH Receptor Antagonists
Dopamine Agonists
Recombinant Human IGF-1

Segment by Application
Hospitals
Clinics
Others

Table of Contents

Executive Summary
1 Acromegaly and Gigantism Drugs Market Overview
1.1 Product Overview and Scope of Acromegaly and Gigantism Drugs
1.2 Acromegaly and Gigantism Drugs Segment by Type
1.2.1 Global Acromegaly and Gigantism Drugs Production Growth Rate Comparison by Type (2014-2025)
1.2.2 Somatostatin Analogs
1.2.3 GH Receptor Antagonists
1.2.4 Dopamine Agonists
1.2.5 Recombinant Human IGF-1
1.3 Acromegaly and Gigantism Drugs Segment by Application
1.3.1 Acromegaly and Gigantism Drugs Consumption Comparison by Application (2014-2025)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.3 Global Acromegaly and Gigantism Drugs Market by Region
1.3.1 Global Acromegaly and Gigantism Drugs Market Size Region
1.3.2 North America Status and Prospect (2014-2025)
1.3.3 Europe Status and Prospect (2014-2025)
1.3.4 China Status and Prospect (2014-2025)
1.3.5 Japan Status and Prospect (2014-2025)
1.3.6 Southeast Asia Status and Prospect (2014-2025)
1.3.7 India Status and Prospect (2014-2025)
1.4 Global Acromegaly and Gigantism Drugs Market Size
1.4.1 Global Acromegaly and Gigantism Drugs Revenue (2014-2025)
1.4.2 Global Acromegaly and Gigantism Drugs Production (2014-2025)

2 Global Acromegaly and Gigantism Drugs Market Competition by Manufacturers
2.1 Global Acromegaly and Gigantism Drugs Production Market Share by Manufacturers (2014-2019)
2.2 Global Acromegaly and Gigantism Drugs Revenue Share by Manufacturers (2014-2019)
2.3 Global Acromegaly and Gigantism Drugs Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Acromegaly and Gigantism Drugs Production Sites, Area Served, Product Types
2.5 Acromegaly and Gigantism Drugs Market Competitive Situation and Trends
2.5.1 Acromegaly and Gigantism Drugs Market Concentration Rate
2.5.2 Acromegaly and Gigantism Drugs Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Acromegaly and Gigantism Drugs Production Market Share by Regions
3.1 Global Acromegaly and Gigantism Drugs Production Market Share by Regions
3.2 Global Acromegaly and Gigantism Drugs Revenue Market Share by Regions (2014-2019)
3.3 Global Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Acromegaly and Gigantism Drugs Production
3.4.1 North America Acromegaly and Gigantism Drugs Production Growth Rate (2014-2019)
3.4.2 North America Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe Acromegaly and Gigantism Drugs Production
3.5.1 Europe Acromegaly and Gigantism Drugs Production Growth Rate (2014-2019)
3.5.2 Europe Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.6 China Acromegaly and Gigantism Drugs Production (2014-2019)
3.6.1 China Acromegaly and Gigantism Drugs Production Growth Rate (2014-2019)
3.6.2 China Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)
3.7 Japan Acromegaly and Gigantism Drugs Production (2014-2019)
3.7.1 Japan Acromegaly and Gigantism Drugs Production Growth Rate (2014-2019)
3.7.2 Japan Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Acromegaly and Gigantism Drugs Consumption by Regions
4.1 Global Acromegaly and Gigantism Drugs Consumption by Regions
4.2 North America Acromegaly and Gigantism Drugs Consumption (2014-2019)
4.3 Europe Acromegaly and Gigantism Drugs Consumption (2014-2019)
4.4 China Acromegaly and Gigantism Drugs Consumption (2014-2019)
4.5 Japan Acromegaly and Gigantism Drugs Consumption (2014-2019)

5 Global Acromegaly and Gigantism Drugs Production, Revenue, Price Trend by Type
5.1 Global Acromegaly and Gigantism Drugs Production Market Share by Type (2014-2019)
5.2 Global Acromegaly and Gigantism Drugs Revenue Market Share by Type (2014-2019)
5.3 Global Acromegaly and Gigantism Drugs Price by Type (2014-2019)
5.4 Global Acromegaly and Gigantism Drugs Production Growth by Type (2014-2019)

6 Global Acromegaly and Gigantism Drugs Market Analysis by Applications
6.1 Global Acromegaly and Gigantism Drugs Consumption Market Share by Application (2014-2019)
6.2 Global Acromegaly and Gigantism Drugs Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Acromegaly and Gigantism Drugs Business
7.1 Ipsen
7.1.1 Ipsen Acromegaly and Gigantism Drugs Production Sites and Area Served
7.1.2 Acromegaly and Gigantism Drugs Product Introduction, Application and Specification
7.1.3 Ipsen Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.1.4 Main Business and Markets Served
7.2 Novartis
7.2.1 Novartis Acromegaly and Gigantism Drugs Production Sites and Area Served
7.2.2 Acromegaly and Gigantism Drugs Product Introduction, Application and Specification
7.2.3 Novartis Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.2.4 Main Business and Markets Served
7.3 Pfizer
7.3.1 Pfizer Acromegaly and Gigantism Drugs Production Sites and Area Served
7.3.2 Acromegaly and Gigantism Drugs Product Introduction, Application and Specification
7.3.3 Pfizer Acromegaly and Gigantism Drugs Production, Revenue, Price and Gross Margin (2014-2019)
7.3.4 Main Business and Markets Served

8 Acromegaly and Gigantism Drugs Manufacturing Cost Analysis
8.1 Acromegaly and Gigantism Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Acromegaly and Gigantism Drugs
8.4 Acromegaly and Gigantism Drugs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.2 Acromegaly and Gigantism Drugs Distributors List
9.3 Acromegaly and Gigantism Drugs Customers

10 Market Dynamics
10.1 Market Trends
10.2 Opportunities
10.3 Market Drivers
10.4 Challenges
10.5 Influence Factors

11 Global Acromegaly and Gigantism Drugs Market Forecast
11.1 Global Acromegaly and Gigantism Drugs Production, Revenue Forecast
11.1.1 Global Acromegaly and Gigantism Drugs Production Growth Rate Forecast (2019-2025)
11.1.2 Global Acromegaly and Gigantism Drugs Revenue and Growth Rate Forecast (2019-2025)
11.1.3 Global Acromegaly and Gigantism Drugs Price and Trend Forecast (2019-2025)
11.2 Global Acromegaly and Gigantism Drugs Production Forecast by Regions (2019-2025)
11.2.1 North America Acromegaly and Gigantism Drugs Production, Revenue Forecast (2019-2025)
11.2.2 Europe Acromegaly and Gigantism Drugs Production, Revenue Forecast (2019-2025)
11.2.3 China Acromegaly and Gigantism Drugs Production, Revenue Forecast (2019-2025)
11.2.4 Japan Acromegaly and Gigantism Drugs Production, Revenue Forecast (2019-2025)
11.3 Global Acromegaly and Gigantism Drugs Consumption Forecast by Regions (2019-2025)
11.3.1 North America Acromegaly and Gigantism Drugs Consumption Forecast (2019-2025)
11.3.2 Europe Acromegaly and Gigantism Drugs Consumption Forecast (2019-2025)
11.3.3 China Acromegaly and Gigantism Drugs Consumption Forecast (2019-2025)
11.3.4 Japan Acromegaly and Gigantism Drugs Consumption Forecast (2019-2025)
11.4 Global Acromegaly and Gigantism Drugs Production, Revenue and Price Forecast by Type (2019-2025)
11.5 Global Acromegaly and Gigantism Drugs Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer